Encube Ethicals IPO: DRHP, Issue Size, Business Model, Financials and Key Risks 

Encube Ethicals is a specialised pharmaceutical formulations company focused on topical and transdermal drug delivery. The business has evolved from contract manufacturing into an integrated platform spanning product development, manufacturing and commercialisation across regulated markets and India. 

Its operating model has three engines: Global Generics, Global CDMO and India Branded Formulations. The Global Generics business has become the fastest-growing vertical, while CDMO still contributes a large and recurring base of customer-led manufacturing revenue. The combination gives Encube exposure to both owned product economics and contract manufacturing relationships. 

Encube Ethicals IPO is an offer for sale of up to ₹3,000 crore. There is no fresh issue. This means the company will not receive IPO proceeds and the balance sheet will not be directly strengthened by the offer. The investment case therefore rests on the underlying business trajectory, R&D productivity, regulatory execution, manufacturing utilisation and cash conversion. 

Encube Ethicals IPO dates and launch details 

Encube Ethicals IPO price band and investment details 

Encube Ethicals IPO structure 

Because the IPO is entirely an OFS, all net offer proceeds will go to the selling shareholders. Encube itself will not receive funds from the transaction. There is therefore no IPO-funded capex, working-capital infusion or debt repayment to model at this stage. 

About Encube Ethicals  

Encube serves customers across 50 countries and operates through three complementary verticals. Its focus is unusually concentrated: topical and transdermal formulations are not one therapy area within a diversified portfolio; they are the core of the company’s development and manufacturing platform. 

Three operating verticals 

 The revenue mix has shifted materially towards Global Generics. Its share increased from 32.36% in FY24 to 46.61% in FY26, supported by a 56.62% CAGR in revenue over the period. CDMO revenue still grew, but at a slower 15.17% CAGR. This mix shift matters because owned generics can offer stronger economics, but they also carry higher exposure to product launches, price erosion, channel concentration and regulatory outcomes. 

R&D and product pipeline 

Product development is central to Encube’s economics. R&D expenditure recognised as an expense was ₹137.6 crore in FY26, or 7.44% of revenue. As of March 2026, Encube had cumulatively filed 73 ANDAs with the USFDA, received 57 approvals and commercialised 51. During FY26 alone, it filed 13 ANDAs and received 14 approvals. The R&D team comprised 228 employees, including 12 PhDs. 

Manufacturing footprint and utilisation 

Encube operates manufacturing facilities in Goa and Indore. On a bulk production basis, aggregate installed capacity was 15,624 metric tonnes in FY26 and utilisation was 81.12%, up from 59.85% in FY24. The Indore facility reached 96.67% utilisation in FY26 and its installed capacity was subsequently expanded from 3,960 tonnes to 9,720 tonnes. 

Filling and packaging capacity tells a different story. Encube had 807 million units of installed filling and packaging capacity in FY26, but utilisation was 27.63%. The company therefore has meaningful downstream capacity headroom, while the economics of the new Indore expansion will depend on how quickly incremental volumes are absorbed. 

Encube Ethicals financial performance 

Growth has accelerated 

Revenue grew 23.84% in FY25 and 37.47% in FY26. PAT grew faster, rising from ₹156.1 crore in FY24 to ₹436.7 crore in FY26. EBITDA margin expanded from 27.41% to 35.88% over the same period. The combination points to favourable mix, scale benefits and stronger material economics rather than revenue growth alone. 

Margin expansion is meaningful, but R&D remains a core cost 

Material margin improved from 67.34% in FY24 to 70.41% in FY26. EBITDA margin rose by more than eight percentage points across the period. Encube also reports EBITDA before R&D, which reached ₹800.9 crore in FY26 with a 43.32% margin. Investors should not treat R&D as optional, however. For a product-led topical formulations business, sustained development spend is part of maintaining the future filing and launch pipeline. 

Cash conversion has improved, but FY26 working capital absorbed growth 

Operating cash flow increased from ₹181.9 crore in FY24 to ₹303.1 crore in FY26, but it was almost flat versus FY25 despite a 75% rise in PAT. The main drag in FY26 was a ₹193.1 crore increase in trade receivables, alongside inventory and other working-capital absorption. Net working-capital days remained high at 143 days, broadly unchanged from FY24. 

The free-cash-flow trend is better than FY24, when heavy capex pushed FCF to negative ₹96.8 crore. FCF turned positive in FY25 and remained positive at ₹101.9 crore in FY26 despite ₹201.4 crore of PPE/CWIP/intangible purchases. The next test is whether cash generation can scale with the faster generics business while receivables remain controlled. 

Borrowings and leverage 

 Leverage has reduced relative to earnings. Balance-sheet borrowings fell slightly to ₹221.7 crore in FY26, while the DRHP’s total-debt-to-EBITDA ratio improved to 0.37x from 0.84x in FY24. Since the IPO is an OFS, this trajectory will continue to depend on internal cash generation rather than fresh issue proceeds. 

Sector and market context 

Encube is positioned within topical pharmaceuticals, a category that combines technical formulation complexity with regulated manufacturing requirements. Its business is exposed to both generic-drug economics and CDMO outsourcing trends. 

• The global topical molecule CDMO market was estimated at about US$5 billion in FY26 and is projected in the DRHP industry report to reach about US$8 billion by FY31, implying an 8% CAGR.
• In India, topical formulations are supported by dermatology demand, consumer skin-health spending and long-lived branded franchises. Cosmo-dermatology represented 35.32% of the Indian topical market in FY26.
• The company’s capabilities cover 67.16% of the US prescription topical molecule market by volume, based on the DRHP industry report, with planned capability additions expected to broaden the addressable set.
• US exposure is already substantial: revenue attributable to products manufactured for the United States represented 64.70% of FY26 revenue from operations. 

Key considerations for investors 

Strengths 

• Focused topical and transdermal expertise across development, manufacturing and commercialisation, rather than a broad multi-dosage-form model.
• Fast-growing Global Generics vertical, which increased from ₹351.3 crore in FY24 to ₹861.7 crore in FY26.
• Established CDMO base with more than 160 customers across 50 countries as of March 2026, providing diversification across product-development and manufacturing mandates.
• Strong recent profitability progression, with EBITDA margin rising from 27.41% in FY24 to 35.88% in FY26 and PAT margin reaching 23.62%.
• Regulatory manufacturing footprint: the Goa facility has approvals from multiple global authorities and the Indore facility has been inspected by the USFDA. 

Risks 

• Customer concentration remains material. The top 10 customers generated 59.74% of FY26 revenue, while the top five Global CDMO customers represented 68.06% of CDMO revenue.
• Manufacturing concentration is high. The Goa facility contributed 85.12% of FY26 revenue from operations, making regulatory or operational disruption at this site a major risk.
• US dependence is significant. The United States accounted for 64.70% of FY26 revenue attributable to products manufactured by geography, exposing the business to US generic pricing, channel and regulatory dynamics.
• Working capital remains intensive at 143 days. FY26 receivables rose sharply and prevented operating cash flow from keeping pace with profit growth.
• R&D productivity is critical. Product filings require material upfront investment and regulatory approval does not guarantee timely commercialisation or attractive economics.
• The IPO is a pure OFS, so the company receives no fresh capital from listing. Investors should not assume an IPO-funded reduction in debt or acceleration in capex. 

Opportunities and monitorables 

• Commercialisation of the expanding ANDA pipeline and the balance between newly approved products and price erosion in older products.
• Ramp-up of the expanded Indore production capacity and whether filling/packaging headroom translates into stronger asset utilisation.
• Further wallet-share gains with CDMO customers, particularly where long-term or take-or-pay arrangements support recurring volumes.
• Growth of India Branded Formulations beyond Soframycin through new prescription and consumer-health products.
• Cash conversion as the business scales, particularly receivable growth, inventory requirements and free cash flow after R&D and capex. 

How to interpret the IPO structure 

An OFS transfers shares from existing shareholders to public investors. It does not inject capital into the company. In Encube’s case, the proposed ₹3,000 crore offer is split between the promoter selling shareholder and Frontier Investment Holdings. Therefore, post-listing operating capacity, working capital and debt service will continue to be funded from the company’s own balance sheet and cash generation unless it raises capital separately in the future. 

Conclusion 

Encube Ethicals enters the IPO process with a differentiated pharmaceutical model: deep topical expertise, a rapidly scaling Global Generics business, an established CDMO platform and a smaller India branded franchise. The last three years show strong revenue growth, margin expansion and lower leverage relative to earnings. The ANDA pipeline and manufacturing capabilities provide visible building blocks for future growth. 

The key counterweights are equally clear. Revenue is concentrated among large customers, the Goa facility is operationally critical, US exposure is high and working capital remains intensive. FY26 also shows that profit growth does not automatically translate into equivalent cash-flow growth when receivables expand. Since the IPO is entirely an OFS, these operating and cash-conversion variables matter more than any expectation of balance-sheet transformation from the listing.